Affiliation:
1. School of Pharmacy and Pharmacology, University of Tasmania, Private Bag 26, Hobart, TAS 7001, Australia
2. Launceston Clinical School, Tasmanian School of Medicine, University of Tasmania, 41 Frankland St, Launceston, TAS 7250, Australia
Abstract
Objective: Little research has evaluated trends in psychotropic prescribing and polypharmacy in primary care patients, especially those with dementia. We sought to examine this in Australia from 2011 to 2020 using the primary care dataset, MedicineInsight. Methods: Ten consecutive serial cross-sectional analyses were performed to evaluate the proportion of patients aged 65 years or more, with a recorded diagnosis of dementia, who were prescribed psychotropic medications within the first six months of each year from 2011 to 2020. This proportion was compared with propensity score-matched control patients without dementia. Results: Before matching, 24,701 patients (59.2% females) with, and 72,105 patients (59.2% females) without, a recorded diagnosis of dementia were included. In 2011, 42% (95% confidence interval [CI] 40.5–43.5%) of patients in the dementia group had at least one recorded prescription of a psychotropic medication, which declined to 34.2% (95% CI 33.3–35.1%; p for trend < 0.001) by 2020. However, it remained unchanged for matched controls (36% [95% CI 34.6–37.5%] in 2011 and 36.7% [95% CI 35.7–37.6%] in 2020). The greatest decline in the dementia groups by medication class was for antipsychotics (from 15.9% [95% CI 14.8–17.0%] to 8.8% [95% CI 8.2–9.4%]; p for trend < 0.001). During this period, the prevalence of psychotropic polypharmacy (use of two or more individual psychotropics) also decreased from 21.7% (95% CI 20.5–22.9%) to 18.1% (95% CI 17.4–18.9%) in the dementia groups, and slightly increased from 15.2% (95% CI 14.1–16.3%) to 16.6% (95% CI 15.9–17.3%) in the matched controls. Conclusions: The decline in psychotropic prescribing, particularly antipsychotics, in Australian primary care patients with dementia is encouraging. However, psychotropic polypharmacy still occurred in almost one in five patients with dementia at the end of the study period. Programs focused on encouraging further reductions in the use of multiple psychotropic drugs in patients with dementia are recommended, particularly in rural and remote regions.
Reference45 articles.
1. WHO (2023, April 24). Dementia. Available online: https://www.who.int/news-room/fact-sheets/detail/dementia.
2. National Centre for Social and Economic Modelling (NATSEM) (2022, November 15). 2018 Dementia Prevalence Estimates 2018–2058. Available online: https://www.dementia.org.au/sites/default/files/2021-03/2021-DA-Prev-Data-Dementia-in-Aus.pdf.
3. Australian Institute of Health and Welfare (2022, June 20). Dementia in Australia, Available online: https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/australian-stories-about-living-with-dementia.
4. Laurie Brown, H.A.L. (2017). Economic Cost of Dementia in Australia 2016 to 2056, National Centre for Social and Economic Modelling (NATSEM) at the Institute for Governance and Policy Analysis, University of Canberra.
5. Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress;Magierski;Front. Pharmacol.,2020